News dated
On 10 November, WHO published the third edition of its catalogue linking mutations in the tuberculosis bacterium with drug resistance. Its evidence base includes more than 71,000 clinical Mycobacterium tuberculosis isolates from over 75 countries. Isolates are bacterial samples studied in laboratories, not a count of people cured. [1][2]
The reference helps laboratories and researchers interpret molecular and sequencing tests, using updated mutation classifications and interpretation rules. Evidence for new and repurposed medicines has also expanded. It supports diagnostics, surveillance and research; it is not a new medicine or a guarantee that treatment already reaches everyone who needs it. [1][2]
The bright side
A broader shared reference can support more consistent interpretation of drug-resistance tests. [1][2]
One idea, in simple words
Tuberculosis is an illness caused by a bacterium. Some bacteria have changes in their genetic material that can make them resistant to particular medicines. Resistant means that a medicine may not work as expected against that bacterium. On 10 November, WHO updated a catalogue that helps laboratories interpret these changes. It draws on more than 71,000 clinical bacterial samples from over 75 countries. It is not a new medicine, and the samples do not count how many people have been cured. As an example, imagine a guide to interpreting difficult signals: the catalogue gives specialists a shared reference. Understanding tests better is a useful step, but it does not replace access to treatment. [1][2]
A little discovery to keep
What did you discover?
Straight from the source.
- WHO updates global catalogue for interpreting tuberculosis drug-resistance mutations World Health Organization · 10 Nov 2026
- Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, 3rd ed. World Health Organization · 10 Nov 2026
Original reporting summaries prepared with AI assistance and accessible sources. Our editorial method.
